CompletedNot Applicable

Describing Patient With DME, Their Patient Journey and Disease Progression

United States221,004 participantsStarted 2023-08-03

Plain-language summary

This study aims to characterize patients with diabetic macular edema (DME), their progression, the treatment received and associate the functional and physiological outcomes related to the treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: All patients ≥18 years, with a DME diagnosis in at least one eye, included in the Vestrum database identified during the study period (January 2015 to April 2023) Exclusion Criteria: Patients without the information of laterality will be excluded.

What they're measuring

Change in visual acuity

Timeframe: From January 2015 to April 2023

Progression to DME in the fellow eye

Timeframe: From January 2015 to April 2023

Initial treatment of DME

Timeframe: From January 2015 to April 2023

Central retinal thickness (CRT)

Timeframe: From January 2015 to April 2023

Trial details

NCT IDNCT05966753

SponsorBoehringer Ingelheim

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-12-31

View on ClinicalTrials.gov More Diabetic Macular Edema trials